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MICALs (molecules interacting with CasL) are atypical multidomain flavoenzymes with diverse cellular
functions. The molecular pathways employed by MICAL proteins to exert their cellular effects remain largely
uncharacterized. Via an unbiased proteomics approach, we identify MICAL-1 as a binding partner of NDR
(nuclear Dbf2-related) kinases. NDR1/2 kinases are known to mediate apoptosis downstream of the mamma-
lian Ste-20-like kinase MST1, and ablation of NDR1 in mice predisposes the mice to cancer as a result of
compromised apoptosis. MST1 phosphorylates NDR1/2 kinases at their hydrophobic motif, thereby facilitating
full NDR kinase activity and function. However, if and how this key phosphorylation event is regulated are
unknown. Here we show that MICAL-1 interacts with the hydrophobic motif of NDR1/2 and that overexpres-
sion or knockdown of MICAL-1 reduces or augments NDR kinase activation or activity, respectively. Surpris-
ingly, MICAL-1 is a phosphoprotein but not an NDR or MST1 substrate. Rather, MICAL-1 competes with
MST1 for NDR binding and thereby antagonizes MST1-induced NDR activation. In line with this inhibitory
effect, overexpression or knockdown of MICAL-1 inhibits or enhances, respectively, NDR-dependent proapo-
ptotic signaling induced by extrinsic stimuli. Our findings unveil a previously unknown biological role for
MICAL-1 in apoptosis and define a novel negative regulatory mechanism of MST-NDR signaling.
Protein kinases are key regulatory enzymes that control im-
portant cellular processes such as growth and apoptosis by
changing the properties of a substrate through phosphorylation
(20). Given the importance of their biological effects, the cat-
alytic activity of protein kinases is stringently controlled, and
defects in this spatiotemporal regulation can cause major dis-
eases such as diabetes and cancer (20). The mammalian Ste-
20-like kinase MST1 is part of evolutionary conserved signal
transduction pathways with functions in different biological
processes of cells. In particular, Hippo signaling (the MST1 fly
ortholog) has been studied extensively in Drosophila melano-
gaster, revealing that Hippo tumor suppressor cascades are
crucial in the regulation of cell death and proliferation (45).
More recently, mammalian MST1 was established as a tumor
suppressor protein controlling cell proliferation and apoptosis
(45). However, despite these important functions, relatively
little is known about the regulation of MST1 or its downstream
signaling.
Nuclear-Dbf2-related kinase 1 (NDR1; also known as
STK38) and NDR2 (STK38L) can be phosphorylated by MST
kinases and mediate apoptotic signaling downstream of MST1
(40). NDR kinases belong to the AGC kinase subfamily and
control important cellular processes, such as mitotic exit and
apoptosis, in different eukaryotic cells ranging from yeast to
neurons (12). Ablation of NDR1 in mice predisposes the mice
to the development of T cell lymphoma, presumably as a result
of compromised apoptosis (4). The regulation of NDR1/2 ki-
nases by MST kinases and other upstream signaling proteins is
best understood in mammalian cells. Binding of MOB1A
(Mps-one-binder 1A) to the N-terminal region of NDR1/2
stimulates autophosphorylation on the activation segment and
activates NDR kinases (3). The human MOB protein family
consists of six distinct members with MOB1 being best studied
for its putative tumor suppressive functions through the regu-
lation of NDR/LATS kinases. Additional phosphorylation on
the C-terminal hydrophobic motif of NDR1/2 by MST kinases
is required for full NDR kinase activation (32). It is evident
that these different molecular interactions and activating
events need to be tightly controlled, as deregulation of mem-
bers of the MST, NDR, and MOB protein families has been
implicated in diseases such as cancer. Intriguingly, another
MOB family member, MOB2, competes with MOB1 for
NDR1/2 binding at the NDR N-terminal region, thereby neg-
atively regulating NDR1/2 kinase activity and related functions
in centrosome duplication and apoptosis (16). However,
whether similar sophisticated regulatory mechanisms exist to
control the activation of NDR1/2 by MST kinases is unknown.
Here we identify the multidomain flavoprotein monooxy-
genase MICAL-1 (MICAL stands for molecule interacting
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with CasL) (37) as an endogenous binding partner of NDR1/2
kinases. Our findings define a previously unknown biological
role for MICAL-1 in apoptosis regulation and show that
MICAL-1 negatively controls MST1-NDR apoptotic signaling
by competing with MST1 for NDR binding, thereby revealing
a novel and unique regulatory mechanism of the MST-NDR
pathway. This work opens new avenues for the further molec-
ular delineation of MST/NDR functioning in different cell
biological processes and in disease.
MATERIALS AND METHODS
Antibodies and reagents. The generation and purification of anti-T444/442-P
and anti-S281/282-P antibodies has been described previously (38). Both anti-
bodies were kindly provided by Brian Hemmings (Friedrich Miescher Institute
for Biomedical Research [FMI], Basel, Switzerland). It is important to note that
the anti-T444-P and anti-S281-P antibodies recognize the phosphorylated forms
of both NDR isoforms, NDR1 (T444-P and S281-P) and NDR2 (T442-P and
S282-P). A polyclonal rabbit anti-mouse MICAL-1 antibody was generated by
immunizing rabbits with a maltose-binding protein (MBP)–mouse MICAL-1
(mMICAL-1) (amino acid 986 to 1048) fusion protein, which was purified from
Escherichia coli DH5 cells. The specificity of this antibody was confirmed using
Western blotting and immunocytochemistry. We used the following commer-
cially available antibodies: anti-Flag (M2; Stratagene), antihemagglutinin (anti-
HA) (3F10; Roche), anti-NDR1 (N-14; Santa Cruz), anti-STK38 (NDR1) mono-
clonal antibody (2G8-1F3; Abnova), CH11 (Millipore), anti-glutathione
S-transferase (anti-GST) (Cell Signaling), anti-myc (Cell Signaling), anti-green
fluorescent protein (anti-GFP) (Invitrogen), anti-V5 (Invitrogen), anti--tubulin
(Sigma), antiactin (Sigma), anti-cleaved caspase-3 (Cell Signaling), and anti-
poly(ADP-ribose) polymerase (anti-PARP) Asp241 (BD Biosciences). Okadaic
acid (OA) was purchased from Enzo Life Sciences, and etoposide, tumor necro-
sis factor alpha (TNF-), and cycloheximide (CHX) were purchased from Sigma.
Construction of plasmids. Mouse MICAL-1 and NDR1 cDNAs were ampli-
fied from embryonic whole-brain cDNA using standard molecular techniques. To
construct a mouse MICAL-1-Flag/HA construct for generating stable L cell
lines, mouse MICAL-1 cDNA was subcloned into a pBABE-Flag-HA-puromycin
destination vector using the Gateway cloning system (Invitrogen). Mouse
MICAL-1 cDNA was also subcloned into pRK5-HA and pRK5-myc (N-terminal
tags) using SalI and NotI restriction sites, into pEF-His/V5 vector (C-terminal
tag) using the Gateway cloning system (Invitrogen), and into pEGFP (EGFP
stands for enhanced green fluorescent protein). Truncation mutants of mouse
MICAL-1 were cloned via PCR. Individual PCR products were digested with
SalI and NotI and cloned into pRK5-HA or pRK5-myc. Mouse MICAL-1 con-
structs harboring glycine-to-tryptophan mutations (G3/W3) in the first FAD
fingerprint were generated in pRK5-myc and pRK5-HA using the QuikChange
site-directed mutagenesis kit (Stratagene). A cDNA encoding the C-terminal 315
amino acids of MICAL-1 was subcloned into the pMAL-P2E vector (BioLabs)
between KpnI and HindIII sites for protein expression in E. coli. Mouse NDR1
was subcloned into pFLAG-CMV4 (Sigma) (CMV stands for cytomegalovirus)
using NotI and BamHI restriction sites. Truncation mutants of mouse NDR1
were cloned via PCR. Individual PCR products were digested with NotI and
BamHI and cloned into pFLAG-CMV4. Flag-NDR2, GST-NDR2, NDR1-
PIFtide, and HA-MST1 have been described before (8, 11). To generate mouse
plexinA4ecto, a region covering amino acids 1209 to 1891 of the mouse plexin
A4 coding sequence was PCR amplified and combined with the plexin A4 signal
sequence and a myc tag in the pSG5 vector. All constructs were confirmed by
sequence analysis.
To knockdown human MICAL-1 in cells, SMARTpool technology from Dhar-
macon was used. A mix of ON-TARGETplus small interfering RNAs (siRNAs)
directed against sequences UGGAGAACAUUGUGUACUA, CCUCAGGCA
CCAUGAAUAA, GAGUCCACGUCUCCGAUUU, and GUACGAGACCU
GUAUGAUG (Dharmacon) in human MICAL-1 was transiently transfected
into cells and efficiently reduced MICAL-1 levels. An ON-TARGETplus non-
targeting siRNA pool from Dharmacon served as a control. To knock down
mouse MICAL-1 in L cells, a siRNA oligonucleotide against mouse MICAL-1
(CAGGUGCCAUGACUAAGUAUU [Dharmacon]) was transfected using
Oligofectamine and shown to specifically reduce MICAL-1 levels. Nontargeting
siRNAs (Dharmacon) were used as controls. To knock down NDR1/2 in L cells,
a short hairpin RNA (shRNA) vector targeting both NDR1 and NDR2 (38) was
transfected using Lipofectamine 2000 (Invitrogen).
Cell culture and transfection. L, Phoenix, HEK293, and COS-7 cells were
maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM;
GIBCO) supplemented with 10% fetal bovine serum (FBS) (Lonza), penicillin-
streptomycin, and L-glutamine (PAA) at 37°C with 5% CO2. U2OS T-Rex
(tetracycline-inducible MST1 knockdown) cells were cultured as described pre-
viously (38). To induce tetracycline-controlled transcriptional activation and
MST1 knockdown, 5  104 cells were plated in one well of a six-well plate and
2 g/ml tetracycline was supplied to the culture medium. For protein analysis,
exponentially growing cells were plated at 3.5  104 cells/cm2 and transfected the
next day using Lipofectamine 2000 (Invitrogen) as described by the manufac-
turer. For COS-7 cell contraction assays or colocalization experiments, 0.5  104
COS-7 cells/cm2 were seeded on glass coverslips and transfected using FuGENE
transfection reagent (Roche) according to the manufacturer’s instructions. For
transfection of MICAL-1 siRNA oligonucleotides, exponentially growing
HEK293 cells or L cells were seeded at 5  104 per well in a 6-well plate. After
overnight culture, cell were washed with Opti-MEM (Invitrogen) and exposed to
a mixture of 1 l oligonucleotides (mix) (from a 20 M stock) and 3 l Oligo-
fectamine (Invitrogen) in Opti-MEM. Four hours after transfection, the medium
was replaced with standard culture medium, and the cells were incubated at 37°C
with 5% CO2 for another 48 to 72 h. For double-knockdown experiments with
both siRNA oligonucleotides (against MICAL-1) and shRNA vector (against
NDR1/2), 5  104 L cells were plated in a 6-well plate 1 day before transfection
of MICAL-1 oligonucleotide using Oligofectamine. After 24 to 48 h in culture,
the cells were transfected with shRNA vector by using Lipofectamine 2000 and
cultured for another 48 h for further treatment.
Generation of stable cell lines. A mouse MICAL-1 cDNA was introduced by
Gateway cloning into a retroviral destination plasmid derived from pBABE-puro
(puro stands for puromycin) carrying a C-terminal Flag PreScission HA tag. L
cell clones expressing tagged MICAL-1 were obtained by retroviral transduction
and puromycin (Clontech) selection. Positive clonal cell lines were identified by
immunoblotting using antibodies directed against HA. After puromycin selec-
tion, clonal lines were maintained in culture medium containing 7.5 g/ml pu-
romycin. L cells with integrated empty pBABE-puro plasmid served as a control.
Pulldown from stable cell lines. Mouse cells expressing MICAL-1-Flag/HA
(MICAL-1 tagged with Flag or HA) (D1) and control (C0) L cells were cultured
in 500-cm2 plates (Corning) to 90% confluence. Ten plates from each cell line
were harvested by scraping the cells after 2 washes with cold phosphate-buffered
saline (PBS). The cells were centrifuged at 1,000 rpm for 15 min at 4°C and lysed
by Dounce homogenization in 3 ml of hypotonic lysis buffer containing 10 mM
HEPES (pH 8.0), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), 0.5 mM dithiothreitol (DTT), and protease inhibitor cocktail
(Sigma). After the cells were centrifuged at 14,000 rpm for 15 min at 4°C, the
supernatant was transferred to a clean Falcon tube, and an equal volume of 2
salt buffer containing 30 mM HEPES (pH 8.0), 190 mM KCl, 30 mM NaCl, 40%
glycerol, 0.4 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT, and protease inhibitor
cocktail (Sigma) was added. After measuring protein concentration, 100 mg
protein from each cell line was added to 100 l prewashed M2 affinity resin
(Sigma) and incubated at 4°C for 3 h. The resin was then washed 4 times with
washing buffer (BC-150) containing 20 mM HEPES (pH 8.0), 150 mM NaCl, and
0.5 mM PMSF. Between the third and fourth wash, the sample was washed once
in washing buffer (BC-300) containing 20 mM HEPES (pH 8.0), 300 mM NaCl,
and 0.5 mM PMSF for 10 min. The proteins were eluted with Flag peptide
(Sigma) at 16 g/l in BC-150 buffer. The eluted proteins were precipitated as
described previously (43) and dissolved in 1 NuPAGE LDS sample buffer
(Invitrogen). Finally, proteins were separated on a NuPAGE Novex 4 to 12%
Bis-Tris gradient gel following the manufacturer’s description (Invitrogen). Pro-
teins were stained using the colloidal blue staining kit (Invitrogen) and processed
for mass spectrometry. In addition, 1/20 of each sample was loaded on another
NuPAGE gel and processed for silver staining. Briefly, the gel was soaked twice
in 50% methanol for 15 min and soaked in 5% methanol for 10 min. After 3
rinses in water, the gel was soaked in 10 M DTT for 20 min, followed by 0.1%
AgNO3 for 20 min. The gel was then washed once in water and twice in developer
containing 3% sodium carbonate and 0.0185% formaldehyde. The gel was
soaked in developer until protein bands appeared. The reaction was stopped with
solid citric acid (about 5% [wt/vol]). The gel was washed with water and scanned.
Gel digestion. Separated proteins were digested in the gel by the method of
Shevchenko et al. (29). Gel lanes corresponding to the different protein samples
were sliced into 10 bands. Each band was cut into 1-mm cubes, washed with
nanopure water, and destained (25 mM ammonium bicarbonate and 50% ace-
tonitrile). After three subsequent destaining steps, the bands were dehydrated
for 20 min (100% acetonitrile) and dried in a vacuum centrifuge. The pellets
were rehydrated in 30 l trypsin solution (0.02 g/l) (Promega) at 4°C for 45
min, followed by the addition of 400 l of 50 mM ammonium bicarbonate to
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cover the gel pieces. After incubating overnight at room temperature, peptides
were extracted two times in 50% acetonitrile in 0.1% trifluoroacetic acid (TFA).
The sample was dried in a vacuum centrifuge prior to liquid chromatography
coupled to matrix-assisted laser desorption ionization mass spectrometry (LC–
MALDI-MS) analysis.
NanoLC and MALDI TOF/TOF analysis. Samples were analyzed as described
previously (22) with minor modifications. In brief, peptides were separated on a
nanocapillary LC (nanoLC) system (LC Packings/Dionex, Sunnyvale, CA) using
an analytical capillary C18 column (150 mm by 100 m inner diameter [ID]) at
400 nl/min, using a linear increase in the concentration of acetonitrile from 5 to
50% (vol/vol) in 90 min and to 90% in 10 min. The eluted gradient was mixed
with matrix solution (7 mg of recrystallized -cyanohydroxycinnaminic acid in 1
ml of 50% (vol/vol) acetonitrile, 0.1% (vol/vol) trifluoroacetic acid, 10 mM
ammonium dicitrate) and spotted off-line to a stainless steel MALDI plate
(Applied Biosystems) to form a predefined 16 by 24 array (384 spots) using a
Probot system (LC Packings/Dionex). The mass spectrometric analysis was car-
ried out using a MALDI tandem time of flight (MALDI-TOF/TOF) instrument
(4800 Proteomics Analyzer; Applied Biosystems) with reflector positive ion
mode. For MS analysis, an m/z mass range of 800 to 3,000 was used with 1,250
shots per spectrum. A maximum of 20 precursors per spot with minimum signal/
noise ratio of 50 were selected for data-dependent tandem MS (MS/MS) anal-
ysis. An 1-kV collision energy was used for collision-induced dissociation
(CID), and 2,500 acquisitions were accumulated for each MS/MS spectrum.
All analyses were performed using default calibration, and the mass accuracy
was calibrated to within 100 ppm using calibration standards (Applied Bio-
systems) before each run.
Cell contraction assay. COS-7 and L cell contraction assays were performed as
described previously (28, 36). In brief, COS-7 or L cells were transfected with
different expression plasmids as described above, fixed after 24 h, and immuno-
stained with anti-Flag, anti-HA, anti-myc, or anti-EGFP antibodies to identify
transfected cells. Immunofluorescent images were captured of randomly selected
cells using a charge-coupled-device (CCD) camera attached to an Axiovert
microscope (Zeiss), and cell area was measured using OpenLab software (Im-
provision) (17). COS-7 cells with a surface area of 1,600 m2 were defined as
contracted. L cell contraction was quantified as described previously (36).
Apoptosis assay. Wild-type L cells or stable C0, D1, or D2 L cells were seeded
at 1  104 cells/cm2 in a 24-well plate for 24 h and treated with either dimethyl
sulfoxide (DMSO) (0.2%) or etoposide (200 M) in the cell culture medium for
12 h. Transiently transfected L cells (overexpressing MICAL-1, MICAL-1 mu-
tants, or knockdown oligonucleotides/vectors) were treated with etoposide 24 h
or 48 h after transfection. L cells were also induced with TNF- (50 ng/ml) for
6 h in the presence of cycloheximide (10 g/ml). For Western blotting, cell
lysates were prepared in 30 l of lysis buffer (per well of a 24-well plate). For
fluorescence microscopy, the cells were fixed and incubated with anti-cleaved
caspase-3 antibody for 1 h at room temperature, followed by several washes and
incubation with anti-rabbit antibody–Alexa Fluor 488. Next, the cells were
washed and incubated with phalloidin-tetramethyl rhodamine isothiocyanate
(TRITC) (Sigma) to visualize cells and cell morphology.
H2O2 detection assay. The Amplex red hydrogen peroxide/peroxidase assay kit
(Invitrogen) was used to measure hydrogen peroxide production from the puri-
fied enzymatic domain of MICAL-1 and from lysates of transfected HEK293 or
L cells as described previously (25, 28). For cell lysate experiments, cells from
one well of a six-well plate were lysed by sonication in 120 l buffer containing
20 mM HEPES (pH 7.4), 100 mM NaCl, and 1 EDTA-free protease inhibitor
mixture (Roche), and lysates were cleared by centrifugation. Reactions were
performed in 100 l consisting of 50 l of cell lysate, 200 M NADPH, Amplex
red reagent (10-acetyl-3,7-dihydroxyphenoxazine), and 0.1 U/ml horseradish per-
oxidase (HRP) in reaction buffer. Absorbance at 560 nm was measured using a
Wallac Victor 1420 multilabel counter (PerkinElmer).
In-gel phosphoprotein staining. Proteins in a NuPAGE Bis-Tris gradient gel
(Invitrogen) were either Coomassie blue stained or stained with Pro-Q diamond
phosphoprotein gel stain (Invitrogen) according to the manufacturer’s instruc-
tions. In brief, the gel was incubated in fix solution (50% methanol and 10%
acetic acid) for 30 min followed by a second overnight incubation. The next day,
the gel was washed 3 times in ultrapure water, stained in Pro-Q stain for 90 min
in the dark, and destained in a solution containing 20% acetonitrile and 50 mM
sodium acetate (pH 4.0). After a brief wash in ultrapure water, the gel was
imaged on a FLA-5000 (Fuji Photo Film Co, Ltd.) using excitation at 532 nm and
LPG filter.
Western blotting and immunoprecipitation. According to standard protocols,
cells were collected by centrifuging at 1,000 rpm for 10 min at 4°C for 10 min,
washed in cold PBS, and lysed in lysis buffer containing 20 mM Tris (pH 8.0), 150
mM KCl, 0.1% Triton X-100, and protease inhibitor cocktail (Roche). After
centrifugation at 14,000 rpm for 10 min at 4°C, the lysate was transferred to a
clean Eppendorf tube and boiled with sample buffer. For immunoprecipitation,
the corresponding antibodies were added to each cell lysate and incubated
overnight at 4°C. Then prewashed protein A- or G-agarose (Roche) was added
to the lysate and incubated for at least 2 h at 4°C. After 4 washes with lysis buffer,
proteins were eluted with sample buffer and boiled at 90°C. To analyze proteins
from immunoprecipitated (IP) samples or cell lysates, we used SDS-PAGE and
transferred proteins to nitrocellulose (Hybond-C Extra; Amersham). Chemilu-
minescence (Supersignal; Thermo Scientific) was detected by CL-XPosure film
(Thermo Scientific) and quantified using ImageJ.
Recombinant protein purification and binding assay. MBP–MICAL-1-C1
(amino acids 734 to 1048) fusion protein was extracted from E. coli DH5 cells,
and the MICAL-1-C1 fragment was cleaved from the MBP moiety following the
instructions of the manufacturer (New England BioLabs). To check the binding
of GST-NDR2 to MICAL-1, HA-tagged MICAL-1 (HA-MICAL-1) (HEK293
cells expressed full-length protein) or MICAL-1-C1 were immobilized on anti-
HA- or anti-MICAL-1-coupled protein G-agarose beads, respectively, and mixed
with 4 g GST-NDR2. Antibody-coupled beads were used as negative control to
examine the nonspecific binding. After 2 h of incubation at 4°C, beads were
washed 4 times with lysis buffer and boiled in the presence of sample buffer. The
proteins were then subjected to SDS-PAGE and Western blot analysis.
Kinase assays. (i) NDR kinase peptide assay. Flag-tagged NDR1 (Flag-
NDR1) was immunoprecipitated from cell lysates expressing Flag-NDR1 alone
or in combination with HA-MICAL-1 and assayed for NDR kinase activity in the
presence of 1 mM NDR substrate peptide (KKRNRRLSVA), 100 M [-
32P]ATP (1,000 cpm/pmol), and 20 M ATP in kinase buffer (20 mM Tris [pH
7.5], 10 mM MgCl2, 1 mM benzamidine, 4 M leupeptin, 3 M microcystin, 3
mM DTT, 1 M cyclic AMP-dependent protein kinase inhibitor peptide). The
reaction mixture was incubated for 60 min at 30°C and stopped by adding 50 mM
EDTA (pH 7.5). The supernatant of the mixture was spotted onto squares of
P-81 phosphocellulose paper (Whatman) and washed 4 times with 1% or-
thophosphoric acid followed by an acetone wash. Radioactivity was measured in
a liquid scintillation counter.
(ii) GST-NDR2 kinase assay using HA-MICAL-1 as a substrate. Full-length
rat recombinant NDR2 was cloned into pGEX4-T 3 in frame with GST, ex-
pressed in E. coli BL21(DE3)(pLysS) cells with 0.03 mM isopropyl--D-1-thio-
galactopyranoside (IPTG) induction overnight at 25°C, and purified by glutathi-
one-Sepharose affinity chromatography. For in vitro kinase assays, 3 g of
GST-NDR2 fusion protein was incubated with immunoprecipitated HA-
MICAL-1 in the presence of 100 M [-32P]ATP (1,000 cpm/pmol) and 20 M
ATP in kinase buffer for 30 min at 30°C. The reaction was stopped by adding
SDS sample buffer, and protein phosphorylation was analyzed by SDS-PAGE
and subsequent autoradiography.
(iii) In vitro phosphorylation with GST-MST1. Recombinant GST-MST1 was
obtained from Sigma. To produce immunopurified HA-tagged proteins, COS-7
cells were transfected and processed for immunoprecipitation using anti-HA
antibody as described earlier (10). Immunopurified proteins were then washed
twice with MST1 kinase buffer (5 mM Tris [pH 7.5], 2.5 mM beta-glycerophos-
phate, 1 mM EGTA, 1 mM Na3VO4, 4 mM MgCl2, 0.1 mM DTT), before
incubating at 30°C for 30 min in 20 l of reaction buffer (5 mM Tris [pH 7.5], 100
M ATP, 2.5 mM beta-glycerophosphate, 1 mM EGTA, 1 mM Na3VO4, 4 mM
MgCl2, 0.1 mM DTT, 10 Ci of [-32P]ATP [3,000 Ci/mmol; Hartmann Ana-
lytic]) in the absence or presence of GST-MST1 (100 ng per reaction mixture).
The reactions were stopped by the addition of Laemmli buffer, before the
proteins were separated by SDS-PAGE. Subsequently, total proteins were visu-
alized by Coomassie blue staining, the gels were then dried, and phosphorylated
proteins were visualized by autoradiography.
RESULTS
Identification of novel MICAL-1-binding partners. MICALs
form a recently discovered and unusual family of evolutionary
conserved cytoplasmic proteins composed of an enzymatically
active flavoenzyme followed by several protein interaction do-
mains or motifs (18). One MICAL gene has been identified in
Drosophila (Mical), while humans and mice have three differ-
ent MICAL genes (MICAL-1, MICAL-2, and MICAL-3) (26,
37, 39). Genetic inactivation of Mical in fruit flies leads to
defects in neural circuit development, myofilament organiza-
tion, and bristle formation (2, 13, 15, 39). Although Drosophila
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Mical has been implicated in the control of F-actin assembly
(13), the molecular pathways employed by MICAL proteins to
exert their diverse cellular effects remain largely uncharacter-
ized, especially in vertebrate species. To obtain more insight
into the MICAL signaling complex and related functions, we
used a retroviral vector system to generate L cell lines that
stably express a Flag-and-HA-tagged (Flag/HA-tagged) ver-
sion of mouse MICAL-1 (MICAL-1-Flag/HA) (Fig. 1A), the
best-characterized vertebrate MICAL thus far (37). Mouse L
cell fibroblasts were used because of their murine origin, their
endogenous MICAL-1 expression and the ability of a consti-
tutively active MICAL-1 construct to induce morphological
changes in these cells (data not shown). This suggests that L
cells contain signaling proteins that are crucial for MICAL-1
function. Clonal cell lines were obtained by retroviral trans-
duction followed by puromycin selection, resulting in several
clones expressing MICAL-1-Flag/HA at near endogenous lev-
els. One of these lines (D1) was used for large-scale affinity
purification of MICAL-1-Flag/HA complexes followed by sil-
ver staining, in-gel tryptic digestion, and mass spectrometry
analysis. L cells with integrated empty retroviral vector served
as a control (C0) (Fig. 1B). The mass spectrometry analysis
identified several proteins that were found in protein com-
plexes from pulldown assays using D1 but not C0 cell extracts.
The most significant hits included the GTP-binding cytoskel-
etal protein septin-9 (42), the serine-threonine kinase NDR1
(12), and the actin-binding protein filamin-B (35) (Table 1).
MICAL-1 interacts with NDR1 and NDR2 kinases. Since
NDR kinases and MICALs display an intriguing overlap in
their reported cellular functions (e.g., neurite growth/pattern-
ing and cytoskeletal dynamics [12, 18]), we focused our efforts
in this study on understanding the role of MICAL-1/NDR
interactions. First, the validity of the NDR1 mass spectrometry
result was confirmed by Western blotting of independent pull-
down samples from C0 and D1 cells with an NDR1-specific
antibody. A prominent 55-kDa band was present specifically in
FIG. 1. Mass spectrometry identifies NDR kinases as novel MICAL-1-binding partners. (A) Schematic depicting the domain organization of
mouse MICAL-1 fused to the C-terminal Flag and HA epitopes linked by a PreScission sequence (MC-1-Flag/HA). FBD, FAD-binding domain;
CH, calponin homology; PPKPP, CasL-binding sequence; CC, coiled-coil. (B) Pulldown assays with anti-Flag monoclonal antibody-conjugated
agarose beads were performed on lysates from D1 or C0 cells. Bound proteins were eluted with Flag peptide and analyzed by silver staining. The
positions of MICAL-1 and NDR1 on the gel are indicated to the left of the gel. (C) Anti-Flag pulldown assays were performed from D1 and C0
cells as shown in panel B and analyzed by Western blotting (WB) using the indicated antibodies (-Flag, anti-Flag antibody). IP, immunopre-
cipitated. (D and E) Lysates from HEK293 cells transfected with epitope-tagged MICAL-1 alone (	) or in combination with Flag-NDR1 (D) or
Flag-NDR2 (E) were immunoprecipitated with anti-Myc (D) or anti-Flag (E) antibodies followed by Western blotting. (F and G) Recombinant
GST-NDR2 and HA-MICAL-1 purified from HEK293 cells (F) or recombinant MICAL-1-C1 purified from bacteria (G) were mixed and subjected
to immunoprecipitation with anti-HA (F) or anti-MICAL-1 (G) antibodies followed by Western blotting with the indicated antibodies. (H) Im-
munoprecipitation from untransfected L cell extracts followed by Western blotting with the indicated antibodies. Anti-myc and anti-HA antibodies
were used as a control for anti-NDR1 and anti-MICAL-1 antibodies, respectively.
TABLE 1. Binding partners of MICAL-1 in stable L cells identified
by mass spectrometrya
Protein Mascotscore
NCBI GI
no.
Protein
MMb
(kDa)
No. of
unique
peptides
MICAL-1 1,956 46396473 116.7 264
Septin-9 554 56749655 65.5 12
NDR1 346 56749663 54.1 8
Filamin-B 318 38257404 277.6 8
a The table shows proteins identified with a significant Mascot score in pull-
down experiments from D1 cell extracts. No peptides were identified for the
indicated proteins in a parallel pulldown from C0 control cells.
b MM, molecular mass.
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the D1 lane following anti-Flag pulldown (Fig. 1C). Immuno-
precipitation experiments from HEK293 cells coexpressing
myc-tagged MICAL-1 (myc-MICAL-1) and Flag-tagged
NDR1 (Flag-NDR1) further confirmed the interaction of
MICAL-1 with NDR1 (Fig. 1D). Using several of the available
antibodies, we were unsuccessful in staining for endogenous
NDR1 or NDR2 in cells (see also references 8 and 10). How-
ever, fluorescence microscopic analysis of COS-7 cells trans-
fected with epitope-tagged MICAL-1 and NDR1 showed that
the distribution of both proteins partially overlapped in the
cytoplasm and in specific membrane regions (data not shown).
Two NDR kinases have been identified, NDR1 and NDR2
(12). NDR1 and NDR2 are 87% identical at the amino acid
level, and one of the peptides identified in our mass spectrom-
etry analysis was shared between NDR1 and NDR2 (data not
shown). It is therefore possible that MICAL-1 also binds to
NDR2. To test this idea, HA-tagged MICAL-1 (HA-MICAL-1)
and Flag-tagged NDR2 (Flag-NDR2) were coexpressed in
HEK293 cells followed by pulldown with anti-Flag antibody.
Indeed, HA-MICAL-1 coprecipitated with Flag-NDR2 (Fig.
1E). A similar result was obtained following coimmunopre-
cipitation of recombinant GST-NDR2 and HA-MICAL-1
protein purified from HEK293 cells (Fig. 1F). To determine
whether the interaction between MICAL-1 and NDR1/2 was
direct, the C-terminal region of MICAL-1 (C1; Fig. 2A) was
purified from bacteria and used in a coimmunoprecipitation
experiment with GST-NDR2. The ability of GST-NDR2 to
coprecipitate MICAL-1 C1 indicates a direct interaction
between NDR2 and the C-terminal region of MICAL-1
(Fig. 1G). Finally, we performed coimmunoprecipitation ex-
periments from naïve L cell lysates using MICAL-1- and
NDR-specific antibodies. Importantly, endogenous MICAL-1 co-
precipitated with endogenous NDR1 and NDR2 and vice
versa from naïve L cell extracts, indicating that in L cells
endogenous MICAL-1/NDR1 complexes can be formed
(Fig. 1H and data not shown).
MICAL-1 and NDR1 interact through domains involved in
the regulation of their enzymatic activity. Both MICAL-1 and
NDR1 are multidomain proteins. MICAL-1 contains an N-ter-
minal flavoprotein monooxygenase (FM) domain, a calponin
FIG. 2. MICAL-1 and NDR1 interact through domains involved in the regulation of their enzymatic activity. (A) Schematic representation of
the domain structure of full-length (FL) mouse MICAL-1 and its truncation mutants. The numbers in parentheses and above the schematic
representation are the amino acid positions. (B) Lysates of HEK293 cells transfected with Flag-NDR1 (	) and HA-tagged full-length or truncated
MICAL-1 were immunoprecipitated (IP) with anti-HA antibody (-HA) and analyzed by Western blotting (WB). (C) Microdensitometry of
Flag-NDR1 coimmunoprecipitated with HA-MICAL-1 (full-length or truncation mutants) from three independent experiments similar to those
shown in panel B. Signal intensity is shown in arbitrary units (a.u.). Values are means plus standard deviations (SD) (error bars). (D) Schematic
depicting NDR1 and its truncation mutants with conserved domains indicated. The positions of the Ser281 and Thr444 regulatory phosphorylation
sites are shown. HM, hydrophobic motif; NTR, N-terminal regulatory region. Numbers indicate amino acid positions. (E) Lysates of HEK293 cells
transfected with HA-MICAL-1 and Flag-tagged full-length or truncated NDR1 were immunoprecipitated with anti-HA antibody and analyzed by
Western blotting. (F) Microdensitometry of Flag-NDR1 coimmunoprecipitated with HA-MICAL-1 (	) from three independent experiments
similar to those shown in panel E. Data are means plus SD. (G) Schematic of the identified interactions between MICAL-1 and NDR1. The LIM
and C-terminal domains of MICAL-1 interact with the C-terminal region of NDR1 harboring the hydrophobic motif and the regulatory Thr444
phosphorylation site.
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homology domain, a LIM domain, proline-rich sequences, and
coiled-coil motifs (Fig. 2A). NDR kinases contain an N-termi-
nal regulatory (NTR) domain, a catalytic domain, and a C-ter-
minal hydrophobic motif (HM) (Fig. 2D). To determine the
domains required for MICAL-1/NDR1 interactions, a series of
truncation mutants were generated for MICAL-1 (Fig. 2A)
(28) and NDR1 (Fig. 2D) (10) and used in pulldown assays
from HEK293 cells coexpressing mutants for MICAL-1 or
NDR1 with full-length NDR1 or MICAL-1, respectively. Co-
precipitation of endogenous MICAL-1 or NDR1 proteins was
not detected in these experimental settings (data not shown).
Intriguingly, constructs containing the LIM (N3, C3, and C2)
and/or C-terminal domain (C3 to C1) of MICAL-1 showed
binding to NDR1, indicating that both domains are required
for association with NDR1 (Fig. 2B and C). Since intramolec-
ular interactions between the LIM and C-terminal domains of
MICAL-1 have been reported to enforce an autoinhibited pro-
tein conformation preventing flavoenzyme activity (28), this
suggests that NDR1 might bind MICAL-1 in its autoinhibited
state. Conversely, the NDR1 C-terminal region was required
for interaction with MICAL-1 (Fig. 2E and F). This is intrigu-
ing because the NDR1 C-terminal region harbors the hydro-
phobic motif surrounding the Thr444 site, whose phosphory-
lation by MST kinases is required for full NDR1 kinase activity
(23, 32, 38). In all, our results reveal an endogenous interaction
between MICAL-1 and NDR1. Furthermore, NDR1 associ-
ates with two domains of MICAL-1 crucial for regulating its
enzymatic activity, while reciprocally, MICAL-1 binds a region
of NDR1 contributing to the control of NDR kinase activity
(Fig. 2G).
MICAL-1 negatively regulates NDR1 kinase activation. To
unveil the functional role of MICAL-1/NDR interactions, we
first explored the idea that NDR kinases regulate MICAL-1.
Thus far, two properties of MICAL-1 have been characterized
in detail. First, MICAL-1 is an NADPH-dependent flavopro-
tein monooxygenase with redox activity (25, 30). Second, C-
terminally truncated MICAL-1 proteins (N1 to N3 [Fig. 2A])
induce cell contraction in culture (28). This contraction re-
sponse is most likely dependent on the FM domain and on
redox activity, as mutagenesis of essential glycine residues in
the MICAL-1 FM domain leads to loss of N1-induced cell
contraction (data not shown). Intramolecular interactions be-
tween the LIM and C-terminal domains of MICAL-1 can in-
hibit FM activity (28). Because NDR1 associates with both
domains, it is tempting to speculate that NDR kinases regulate
MICAL-1 activity. To test this hypothesis, an enzyme-linked
assay was used to determine the effect of NDR1/2 on
MICAL-1 enzymatic activity based on H2O2 production (Fig.
3A and B) (25, 28). In line with previous observations, full-
length (FL) MICAL-1 produced only low levels of H2O2,
whereas constitutively active MICAL-1 N1-N3 truncation mu-
tants showed high enzymatic activity (Fig. 3A to D) (25, 28). In
a recent study, it was shown that cotransfection of the putative
MICAL-1 substrate collapsin response mediator protein-2
(CRMP-2) with MICAL-1 in cells leads to a reduction in
MICAL-1 N1-N3 H2O2 enzymatic activity. Similarly, recombi-
nant GST-CRMP-2 induced a reduction in MICAL-1 N3 en-
zymatic activity (28). It was proposed that rather than produc-
ing H2O2, MICAL-1 may perform redox reactions on CRMP-2
in the presence of this substrate (28). In contrast to these
findings, MICAL-1 activity was not inhibited by the cotrans-
fection of NDR1 or by the addition of recombinant NDR2.
Furthermore, NDR1/2 did not alter the enzymatic activity of
FL MICAL-1 (Fig. 3C and D). In addition, shRNA-mediated
knockdown of NDR1/2 in L cells did not affect the enzymatic
activity of MICAL-1 N3 (Fig. 3E). Previous work has shown
that cotransfection of FL MICAL-1 with CRMP-2 or plexin A1
induces COS-7 cell contraction (28). However, coexpression of
NDR1/2 or a constitutively active form of NDR1 (NDR1-
PIFtide [33]) with FL MICAL-1 did not induce cell contrac-
tion, and NDR1/2 overexpression or knockdown did not influ-
ence contraction triggered by N3 (Fig. 3F and G; also data not
shown). These experimental results argue against a role for
NDR1/2 in the control of MICAL-1 enzymatic and contraction
activity. We next determined whether MICAL-1 could serve as
a substrate for NDR kinases. Although we were able to estab-
lish that MICAL-1 is a phosphoprotein (Fig. 4A), GST-NDR2
failed to phosphorylate MICAL-1 in an in vitro kinase assay,
indicating that MICAL-1 is not an NDR2 substrate (Fig. 4B).
Unfortunately, production of GST-NDR1 protein is notori-
ously difficult, and we were unable to obtain sufficient quanti-
ties of NDR1 for kinase assays. In summary, our results
strongly argue against a direct role for NDR1/2 in regulating
MICAL-1 enzymatic activity and the subsequent cell morpho-
logical changes.
Therefore, we next examined whether MICAL-1 may regu-
late NDR kinases. Multisite phosphorylation is a general con-
trol mechanism of NDR1 and NDR2, which contain two main
regulatory phosphorylation sites: Ser281/282 (NDR1/2, the ac-
tivation segment) and Thr444/442 (the hydrophobic motif)
(Fig. 2D). Upon MOB-1A binding to the N-terminal region,
Ser281/282 is autophosphorylated, whereas Thr444/442 is tar-
geted by upstream MST kinases (12). Treatment of cells with
okadaic acid (OA), which preferentially inhibits protein phos-
phatase 2A, results in increased Ser281/282 and Thr444/442
phosphorylation and elevated NDR1/2 kinase activity (3, 32,
38). To study the potential effects of MICAL-1 on NDR1/2, we
treated HEK293 cells transfected with Flag-NDR1 alone or in
combination with HA-MICAL-1 with OA and assessed Ser281
and Thr444 phosphorylation of precipitated Flag-NDR1 pro-
tein using phospho-specific antibodies (Fig. 5A). Sixty minutes
of OA treatment strongly induced Ser281 and Thr444 phos-
phorylation (data not shown). MICAL-1 overexpression did
not influence OA-induced Ser281 autophosphorylation (Fig.
5A). Consistent with these data, we did not find an effect of
MICAL-1 on GST-NDR2 autophosphorylation in kinase as-
says (Fig. 4B). It should be noted, however, that the currently
available phosphorylated Ser281 (p-Ser281) antibody is not
suitable for work with endogenous NDR kinases (unpublished
data). In striking contrast, overexpression of HA-MICAL-1
drastically inhibited phosphorylation of Flag-NDR1 on Thr444
following OA treatment (Fig. 5A). This effect was dose depen-
dent, as higher levels of HA-MICAL-1 were more efficient in
lowering OA-induced NDR1 phosphorylation (Fig. 5B). Fur-
thermore, MICAL-1 reduced Thr444 phosphorylation of en-
dogenous NDR1 and NDR2 following OA treatment (Fig.
5C). It has been reported that at certain concentrations H2O2
can inhibit Thr444 phosphorylation (8). Since the MICAL-1
FM domain can produce H2O2 under specific conditions or
potentially facilitate other redox reactions (Fig. 3) (25, 28), we
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next asked whether MICAL-1 enzymatic activity mediates the
negative effect of MICAL-1 on Thr444 phosphorylation. Site-
directed mutagenesis was used to mutate the first FAD finger-
print in the MICAL-1 FM domain. These mutations disrupt
FAD binding and block enzymatic activity without affecting the
overall structure of the protein (19, 21, 44). MICAL-1 FL
G3/W3 could, however, still reduce OA-induced Thr444 phos-
phorylation, suggesting that the inhibitory effect of MICAL-1
on Thr444 phosphorylation is independent of its enzymatic
activity (Fig. 5C).
Next, to establish the physiological relevance of the MICAL-1
effect, the level of endogenous MICAL-1 in HEK293 cells was
decreased by siRNA. In line with our previous results, knock-
down of MICAL-1 resulted in an increased level of Thr444
phosphorylation triggered by OA compared to control (Fig.
5D). Thus, MICAL-1 is an endogenous negative regulator of
NDR1 activation in HEK293 cells. Since phosphorylation of
Thr444 is required for full kinase activity, we next examined
the ability of MICAL-1 to reduce NDR1 kinase activity on
NDR substrate peptide (Fig. 5E). Flag-NDR1 was expressed in
HEK293 cells, alone or in combination with HA-MICAL-1,
immunoprecipitated, and used in a peptide kinase assay. In
line with its negative effect on Thr444 phosphorylation,
MICAL-1 robustly inhibited NDR1 kinase activity, reducing
peptide phosphorylation by about 40%. In conclusion, our
results show that MICAL-1 is an endogenous negative regula-
tor of NDR1 activation that inhibits T444 phosphorylation,
thereby contributing to the control of NDR kinase activity.
MICAL-1 negatively regulates the activation of NDR1 ki-
nase by competing with MST1 for NDR1 binding. Phosphor-
ylation on Thr444/442 of NDR1 and NDR2 can be mediated
by MST kinases (32, 40). MST1 can physically associate with
the C-terminal hydrophobic motif of NDR1/2 and phosphor-
ylate Thr444/442 upon activation by upstream signals such as
FIG. 3. NDR kinases have no effect on MICAL-1 enzymatic or cell contraction activity. (A) Schematic representation of the domain structure
of full-length (FL) mouse MICAL-1 and truncation mutants used for H2O2 and COS-7 cell contraction assays. Numbers indicate amino acid
positions. (B) Overview of the enzyme-linked assay used to determine H2O2 levels in two different experiments (see panels C and D) (25, 28). (C
to E) Cell lysates (C and E) (28) and purified proteins (D) (25) were used to study MICAL-1 enzymatic activity in the presence (	) or absence
(
) of NDR1/2 kinases. (C and E) Measurement of H2O2 production from lysates of HEK293 cells (C) or L cells (E) transfected with the indicated
constructs in the presence of 200 M NADPH. The gels below the graphs in panels C and E show a representative Western blot analysis of lysates
used for enzymatic reactions. NDR shRNA targets NDR1 and NDR2. (D) Measurement of H2O2 production from purified full-length (FL) and
truncated (N3) MICAL-1 proteins in the presence of different concentrations of GST or GST-NDR2. (F) COS-7 cells were transfected with the
indicated MICAL-1 constructs alone or in combination with NDR1 (1), NDR2 (2), or NDR1-PIFtide (PIF). Transfected cells were immunostained
with anti-GFP (MICAL-1; green) and anti-Flag (NDR1; red) antibodies. (G) Quantification of the cell contraction experiments shown in panel
E (mean plus standard error of the mean [SEM] [error bar]). Cells with an area of 1,600 m2 were defined as contracted.
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RASSF1A. MST1-induced NDR1/2 activation plays a crucial
role downstream of RASSF1A in the apoptotic response to
death receptor stimulation (40). Therefore, the association of
MICAL-1 with the NDR C-terminal region and its ability to
reduce Thr444 phosphorylation induced by OA invite the spec-
ulation that MICAL-1 regulates NDR kinase activation by
interfering with the function of MST kinases. One possible
mechanism could be that MICAL-1 associates with MST ki-
nases and thereby controls their function. To test this model,
we examined whether MICAL-1 can associate with MST1 fol-
lowing overexpression in cells. Although MST1 bound NDR1
(data not shown) (40), no interaction between MST1 and
MICAL-1 was observed (Fig. 6A). Alternatively, MICAL-1
may serve as a substrate for MST1 competing with NDR ki-
nases for phosphorylation. Therefore, the phosphorylation sta-
tus of MICAL-1 was determined following shRNA-mediated
knockdown of MST1 in cells. Interestingly, MICAL-1 phos-
phorylation was not affected by MST1 knockdown (Fig. 6B).
To further test whether the regulation of NDR kinases by
MICAL-1 involved the phosphorylation of MICAL-1 by MST1
kinase, we analyzed MICAL-1 as an MST1 substrate. This
revealed that while kinase-dead NDR1 [NDR1(kd)] was
strongly phosphorylated by recombinant MST1 (Fig. 6C, lane
5), purified MICAL-1 was not (Fig. 6C, lane 6), although
MICAL-1 was present at higher abundance than NDR1. As
expected, active MST1 also autophosphorylated itself (Fig. 6C,
lanes 4 to 6), and all phosphorylation events were dependent
on the presence of active MST1 (Fig. 6C, lanes 1 to 3). Nota-
bly, no effect of MICAL-1 expression on MST1 autophosphor-
ylation was observed. Taken together, these findings suggest
that MICAL-1 is not an MST1 substrate, arguing against the
possibility that MICAL-1 interferes with phosphorylation of
NDR by MST1 by serving as an alternative MST1 substrate.
A third possibility is that MICAL-1 competes with MST
kinases for binding on the hydrophobic motif of NDR1. To test
this idea, lysates from HEK293 cells expressing Flag-NDR1
and HA-MST1 were mixed with increasing amounts of lysates
from HA-MICAL-1-expressing cells followed by anti-Flag im-
munoprecipitation. Increasing MICAL-1 levels led to a reduc-
tion in the amount of MST1 that coimmunoprecipitated with
NDR1 despite similar MST1 input levels (Fig. 7A). As re-
ported previously (11, 40), overexpression of MST1 leads to an
increase in Thr444 phosphorylation (data not shown). To ex-
amine whether overexpression of MICAL-1 not only reduces
MST1 binding but also causes a consequent decrease in MST1-
induced Thr444 phosphorylation, we expressed HA-MST1 in
combination with increasing amounts of HA-MICAL-1 and
monitored Thr444 phosphorylation of endogenous NDR1/2.
Indeed, MICAL-1 decreased MST1-induced Thr444 phos-
phorylation in a dose-dependent manner (Fig. 7B). In all, these
results establish that MICAL-1 interferes with the binding of
MST1 to NDR1/2, thereby negatively regulating MST1-in-
duced NDR phosphorylation at the hydrophobic motif.
MICAL-1 interferes with apoptosis signaling. Since our
findings indicate that MICAL-1 negatively regulates MST1-
NDR signaling, we sought to determine whether MICAL-1
could affect a known biological function of the MST1-NDR
pathway (40). The activation of NDR1/2 kinases through phos-
phorylation by MST1 is necessary for apoptosis signaling in
mammalian cells (40). In addition, loss of NDR1/2 kinases can
result in resistance to apoptosis (4). Therefore, wild-type L
cells or stable C0 and D1 cells were treated for 12 h with
vehicle or etoposide, a reagent known to induce apoptosis
through NDR kinases (4), harvested, and analyzed by immu-
noblotting (Fig. 8A). Etoposide treatment triggered a robust
increase in Thr444/442 phosphorylation in wild-type (not
shown) and control (C0) cells concomitant with a strong in-
duction of two apoptotic markers, i.e., cleaved PARP and
cleaved caspase-3 (Fig. 8A). Furthermore, many cleaved
caspase-3-positive C0 cells were detected following etoposide
treatment (Fig. 8B). Intriguingly, etoposide exposure of D1
cells expressing MICAL-1-Flag/HA (Fig. 1) did not result in
enhanced Thr444/442 phosphorylation (Fig. 8A). In line with
this prominent inhibition of NDR activation, the signals for
cleaved PARP and cleaved caspase-3 were dramatically lower
in D1 cells than in control C0 cells following etoposide treat-
FIG. 4. MICAL-1 is a phosphoprotein but not a substrate of
NDR2. (A) Lysates from HEK293 cells overexpressing HA-MICAL-1
were subjected to immunoprecipitation with anti-HA antibodies, sep-
arated on a gradient gel, and stained with Pro-Q phosphoprotein stain
or with Coomassie blue to visualize all protein. The full-length form of
mouse MICAL-1 is phosphorylated. Similar results were obtained with
endogenous MICAL-1 protein precipitated from Neuro2A cells or
brain lysate (data not shown). (B) HA-MICAL-1, immunoprecipitated
from HEK293 cells, was used in an in vitro kinase assay with recom-
binant GST-NDR2. (Right) Western blotting was used to detect HA-
MICAL-1 and GST-NDR2 input. MICAL-1 does not display increased
phosphorylation in the presence of GST-NDR2. Conversely, NDR2
autophosphorylation (indicated by the 80-kDa bands) is unaffected by
MICAL-1.
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ment (Fig. 8A), and only a few cleaved caspase-3-positive D1
cells were detected (Fig. 8B), suggesting that apoptotic signal-
ing is inhibited in D1 cells. Similar results were obtained in a
second, independent stable line expressing MICAL-1-Flag/HA
(clone D2; not shown). In addition, the activation of NDR
kinases (phosphorylated Thr444 [pThr444]) and cleavage of
caspase-3 and PARP in response to TNF-/CHX, another
proapoptotic stimulus known to signal through NDR kinases
(40), was reduced in D1 cells than in C0 cells (Fig. 8A). CHX
alone did not induce apoptosis or affect pThr444 levels (40;
also data not shown). Finally, to assess whether the inhibitory
effect of MICAL-1 on apoptosis was dependent on its MO
domain and redox signaling, we transiently transfected the
constitutively active MICAL-1 N3 mutant or the FL MICAL-1
G3/W3 mutant into L cells and treated these cells with etopo-
side. Similar to FL MICAL-1, MICAL-1 G3/W3 reduced the
etoposide-induced cleavage of caspase-3 (Fig. 8C). No effect of
MICAL-1 N3 was observed. These results support the idea that
the inhibitory effect of MICAL-1 on apoptosis is independent
of its MO domain.
We also addressed the role of endogenous MICAL-1 in
apoptosis regulation by RNA interference (RNAi). Wild-type
L cells transfected with non-targeting control siRNAs or
siRNAs specifically targeting mouse MICAL-1 were treated
for 12 h with vehicle or etoposide, harvested, and analyzed by
immunoblotting (Fig. 8D). In line with our biochemical and
overexpression data, knockdown of MICAL-1 resulted in an
increase in the overall amount of Thr444/442 phosphorylated
FIG. 5. MICAL-1 negatively regulates NDR1 kinase activation and activity. (A) HEK293 cells were transfected with Flag-NDR1 alone or in
combination with HA-MICAL-1, treated with okadaic acid (OA) for 60 min and immunoprecipitated with anti-Flag antibody. Thr444 and Ser281
phosphorylation of precipitated NDR1 was assessed by Western blotting (WB) using phospho-specific antibodies (-pT444, antibody against
phosphorylated T4444). (Bottom) Microdensitometry from three independent experiments. Data are means plus SD (error bars). (B) HEK293
cells were transfected with Flag-NDR1 (	) in the absence or presence of different amounts of HA-MICAL-1 (the amount of HA-MICAL-1 is
indicated by the height of the triangle above the lane) and treated with OA for the indicated periods of time (0 min [0] to 30 min [30]). Lysates
were immunoprecipitated with anti-Flag antibodies, analyzed by Western blotting, and quantified (lower panel). The graph below the Western
blots shows microdensitometry of a representative experiment. (C) HEK293 cells were transfected with pRK5 (
), HA-MICAL-1 (	), or
HA-MICAL-1 G3/W3 (G3/W3) and treated with OA for 60 min, and total lysate (TL) was analyzed by Western blotting with the indicated
antibodies. (Bottom) Microdensitometry from three independent experiments. Data are means plus SD. (D) HEK293 cells were transfected with
a SMARTpool of ON-TARGETplus siRNAs against MICAL-1 (	) or with a pool of scrambled control siRNAs (
), treated with OA for 60 min,
and then Western blotted with the indicated antibodies. The graph to the right of the Western blots shows microdensitometry from three
independent experiments. Data are means plus SD. (E) HEK293 cells were transfected with V5-NDR1, alone or in combination with HA-
MICAL-1, and treated with vehicle or OA. Immunoprecipitated V5-NDR1 protein was used for NDR peptide kinase assays. Data from a
representative experiment with two replicate samples is shown. Error bars represent SDs.
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NDR and in increased signals for cleaved PARP and cleaved
caspase-3 (Fig. 8D). Although etoposide and TNF- can in-
duce apoptosis through the MST1-NDR pathway, it is formally
possible that the observed effects of MICAL-1 on apoptosis do
not involve modulation of NDR signaling. To address this
point, L cells were transiently transfected with siRNAs target-
ing MICAL-1, shRNA constructs targeting NDR1/2 or combi-
nations thereof, followed by etoposide treatment. Knockdown
of MICAL-1 led to increased signals for cleaved caspase-3,
while as shown previously (4), knockdown of NDR1/2 inhib-
ited the cleavage of caspase-3 induced by etoposide (Fig.
8E). Interestingly, following simultaneous knockdown of
MICAL-1 and NDR1/2, no induction of caspase-3 cleavage
was observed, indicating that MICAL-1 and NDR1/2 func-
tion in the same pathway. In all, we conclude that MICAL-1
has inhibitory effects on proapoptotic signaling through the
NDR-MST pathway.
DISCUSSION
Phosphorylation of NDR1/2 kinases by MST1 is required for
full NDR kinase activity and for the induction of apoptosis in
response to proapoptotic stimuli (4, 40). The deregulation of
NDR1 and MST kinases predisposes the organism to the de-
velopment of cancer due to compromised apoptotic responses
(4, 31). Despite the critical role of MST-induced NDR phos-
FIG. 7. MICAL-1 competes with MST1 for NDR1 binding. (A) Ly-
sates from HEK293 cells transfected with Flag-NDR1, HA-MST1, or
HA-MICAL-1 were mixed as indicated, immunoprecipitated with anti-
Flag antibodies, and analyzed by Western blotting (WB). (B) HEK293
cells were transfected with HA-MST1 in the presence of different
amounts of HA-MICAL-1. Lysates were subjected to WB with the
indicated antibodies.
FIG. 6. MICAL-1 is not a substrate for MST1 kinase. (A) Lysates from HEK293 cells transfected with HA-MST1 alone or in combination with
MC-1-V5 were immunoprecipitated with anti-V5 antibodies followed by Western blotting (WB). (B) Lysates of U2OS T-Rex cells were transfected
with HA-MC-1 and treated with vehicle (
) or tetracycline (	) to induce MST1 shRNA expression. The lysates were subjected to immunopre-
cipitation with anti-HA antibodies followed by Coomassie blue or Pro-Q staining or WB with the indicated antibodies. The graph shows
microdensitometry from a representative experiment. (C) Lysates of COS-7 cells transiently expressing empty vector, HA-NDR1 kinase-dead
[HA-DNR1(kd)], or HA-MC-1 were subjected to immunoprecipitation with anti-HA antibody. Immunopurified proteins were then processed for
kinase assays without or with GST-MST1. The proteins were then separated by SDS-PAGE and visualized either by autoradiography (top panel)
or Coomassie blue staining. In parallel, samples were analyzed by Western blotting using anti-HA and anti-MST1 antibodies. The positions of
HA-MC-1, GST-MST1, and HA-NDR1 (in kilodaltons) are indicated by arrowheads to the right of the Western blots. The relative molecular
weights (Mr) (in thousands [K]) are indicated to the left of the Western blots.
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phorylation in different cell biological processes and in disease,
it has remained unknown if or how this key phosphorylation
event is regulated. Our findings identify MICAL-1 as a novel
endogenous negative regulator of MST1-NDR signaling and
apoptosis in mammalian cells (Fig. 8F). MICAL-1 specifically
and endogenously interacts with the hydrophobic motif of
NDR1/2 (Fig. 1 and 2) and colocalizes with NDR1 in cells, and
ectopic expression of MICAL-1 reduces NDR kinase activa-
tion and activity (Fig. 5). Knockdown of endogenous
MICAL-1, on the other hand, results in increased NDR kinase
phosphorylation (Fig. 5). Furthermore, we found that
MICAL-1 does not bind MST1 or serve as a MST1 substrate
(Fig. 6) but competes with MST1 for NDR binding (Fig. 7)
and thereby reduces MST1-induced NDR activation (Fig.
7). In line with this inhibitory effect, overexpression and
knockdown studies show that MICAL-1 negatively affects a
known biological function of the MST1-NDR1/2 pathway,
namely, proapoptotic signaling (Fig. 8). Together, these re-
sults uncover a novel and unique regulatory mechanism of
MST-NDR signaling.
Binding of MOB1 to the N-terminal region of NDR1/2 stim-
ulates autophosphorylation and NDR activation (3). Kohler
and colleagues recently reported that human MOB2 (hMOB2)
can act as an inhibitor of hMOB1-NDR signaling by competing
with hMOB1 for binding to the N-terminal domain of NDR1/2
(16). Here we describe an unexpected additional level of NDR
regulation. By competing with MST1 for binding to the C-ter-
minal hydrophobic motif domain, MICAL-1 can regulate
NDR1/2 activation (Fig. 8F). Together, these studies define a
novel level of NDR kinase regulation through competitive
inhibitors that directly interfere with the binding of key up-
stream activating signals, such as MOB1 and MST1. How these
competitive inhibitors are controlled is unknown. It is possible
that previously identified MICAL-1 interactors such as plexin
FIG. 8. MICAL-1 inhibits NDR-dependent apoptotic signaling. (A) Stable C0 and D1 L cells were treated with control compound (DMSO or
CHX [not shown]), etoposide, or TNF-/CHX (4, 40). Lysates were processed for Western blotting using the indicated antibodies. Cleav., cleaved.
(B) Stable C0 and D1 L cells were treated as described above for panel A and immunostained using phalloidin-TRITC (red) to visualize cell
morphology and anti-cleaved caspase-3 (green) antibody. (C) L cells were transiently transfected with empty vector or constructs for FL MICAL-1,
FL MICAL-1 G3/W3, or MICAL-1 N3, treated with etoposide, and processed for Western blotting using the indicated antibodies. (D) L cells were
transfected with non-targeting control siRNA (
) or with siRNA oligonucleotides targeting mouse MICAL-1 (	), treated as described above for
panel A, and processed for Western blotting using the indicated antibodies. The graph shows a quantification of the levels in the Western blots.
(E) L cells were transfected with non-targeting control siRNA or shRNA (
), siRNA oligonucleotides targeting mouse MICAL-1 (	), shRNA
constructs targeting NDR1/2, or combinations thereof, treated as described above for panel A, and processed for Western blotting using the
indicated antibodies. The graph shows a quantification of the levels in the Western blots. (F) Schematic representation of the inhibitory role of
MICAL-1 in the MST1-NDR signaling pathway during apoptosis. P, phosphate.
VOL. 31, 2011 MICAL-1 REGULATES MST-NDR KINASE SIGNALING 3613
proteins contribute to this regulation. Plexins function as evo-
lutionary conserved type I transmembrane receptors for sema-
phorin proteins in different cell types and organ systems and
mediate diverse cellular processes, including apoptosis (7, 27,
46). For example, semaphorin 3A can induce neuron or leu-
kemic cell death through plexin A3 and plexin A1, respectively
(1, 24). Intriguingly, MICAL-1 can associate with the cytoplas-
mic domains of the four class A plexins, and semaphorin ligand
stimulation enhances this interaction (28) (Y. Zhou and R. J.
Pasterkamp, unpublished observations). Recruitment of MICAL-1
to plexin upon ligand stimulation may reduce the availability of
MICAL-1 for inhibiting MST-induced NDR activation, lead-
ing to enhanced NDR activity and apoptosis. Alternatively, the
regulation of MICAL-1 activity by upstream signaling cues
such as protein kinases may be crucial for controlling its in-
hibitory role in the MST-NDR pathway. This idea gains sup-
port from the observation that MICAL-1 is phosphorylated in
cells and neural tissues (Fig. 4A), suggesting that it is a sub-
strate for upstream kinases. Future studies will address these
and other possible mechanisms.
It is plausible that the MICAL-1-dependent regulatory
mechanism delineated in this study also functions in MST-
and/or NDR-dependent cellular processes other than apopto-
sis. For example, the MST1-NDR pathway was recently
implicated in the control of centrosome duplication (11). Fur-
thermore, striking similarities exist between the effects of ma-
nipulating MST, MICAL, and NDR on neuronal morphology.
Knockdown of MST3b or overexpression of constitutively ac-
tive MICAL-1 in cultured mammalian neurons reduces neurite
growth (14, 28), while exogenous NDR2 expression enhances
neurite growth (34). The loss of Tricornered (NDR) or Hippo
(MST) in Drosophila and the loss of SAX-1 (NDR) in Caeno-
rhabditis elegans leads to altered dendritic arborization and
tiling defects (i.e., ectopic overlap between individual dendritic
trees) (5, 6, 9). Loss of Drosophila Mical also results in enlarged
dendritic fields due to deficits in dendritic pruning (15). These
observations together with our own findings support a model in
which MST, MICAL, and NDR are components of a common
molecular pathway that controls the formation and remodeling
of the initial imprecise neuronal network into functional neu-
ronal connections.
In the present study, no effect of NDR1/2 on MICAL-1
enzymatic activity or cell contraction was detected, but it is
possible that NDR1/2 influences other proposed MICAL ef-
fects such as on Rab-mediated vesicle transport (41) or myo-
filament organization (2). It is also interesting to note that
knockdown of MST3b leads to a reduction in CRMP-1, a
putative substrate for the MICAL-1 flavoprotein monooxygen-
ase domain (14, 28). Thus, MICAL-1 may not only negatively
regulate MST kinases, but MSTs might also influence MICAL-1
function by controlling its substrate levels.
Taking all the results of this study together, this study reveals
a previously unknown biological role for MICAL-1 in apopto-
sis and defines a novel negative regulatory mechanism of MST-
NDR signaling. Future experiments are needed to decipher
the precise role of MICAL-1 in the activation of NDR kinases
by extrinsic and intrinsic apoptotic stimuli. Further elucidation
of the role of MICAL-1 in MST-NDR signaling can be ex-
pected to open new avenues for the molecular delineation of
MST/NDR functioning in different cell biological processes
and for understanding how deregulation of this pathway con-
tributes to disease.
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